Welcome to World Class Retina Care

Our practice was established in 1980 in central Phoenix. Since then, we have grown to include more than 35 locations throughout Arizona, providing improved access to the highest quality medical care. We are proud to have become Arizona’s largest and most experienced ophthalmology practice focused specifically on the diagnosis and management of the retina and vitreous.

At RCA, we believe in providing you with professional, attentive, and personal care while utilizing the latest technology and treatments. We accept new patients every day, and urgent or emergency referrals are seen the same day.

Find Your Location Today

Take charge of your eye health!

Making healthy choices and getting regular eye exams can help reduce a person’s risk of vision loss. we encourage everyone to take charge of their eye health and preserve their sight by following some simple tips.

Click here for more!

Latest News From RCA

Pravin U. Dugel, MD – EURETINA 2018 – Brolucizumab For Neovascular Age-Related Macular Degeneration

   At this year’s EURETINA congress, we caught up with Dr Pravin Dugel to discuss neovascular age-related macular degeneration (nAMD). Dr Dugel suggests that while there have been recent advances in the treatment of nAMD, there is still a need to obtain better efficacy and find drugs that maintain visual acuity improvement over the… Read More »

Oculis appoints World-renowned Ophthalmology Specialist Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board

Lausanne, Switzerland, September 24th, 2018 – Oculis, a clinical-stage biotechnology company developing next-generation topical treatments for acute and chronic back- and front-of-the-eye diseases, announces the appointment of Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board (SAB). Dr. Dugel is internationally recognized for his research in the field of ophthalmologic diseases and brings… Read More »

Dr. Pravin Dugel: Kodiak Sciences Announces Completion of Enrollment in the Company’s Phase 1 Safety and Tolerability Study in Patients with Retinal Disease

PALO ALTO, Calif., Aug. 31, 2018 /PRNewswire/ — Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced that enrollment of patients in the company’s phase 1 safety and tolerability study has been completed.  First patient in was dosed on July 12, 2018 and last patient… Read More »